Jessica L. Boklan, MD
You are here: Home > Find a Doctor > Jessica L. Boklan, MD

Jessica L. Boklan, MD

Specialty: Hematology & Oncology

Director, Clinical Oncology Research; Director, Early Drug Development Program; Co-Director, Leukemia, Lymphoma, Histiocytosis Program

Areas of Expertise

  • Pediatric Hematology
  • Pediatric Oncology
  • Pediatrics
  • Leukemia
  • Bone Marrow Failure
  • Cancer Drug Dev.
Phoenix Children's Medical Group - Hematology / Oncology
1919 E Thomas Rd, Phoenix, AZ 85016-7710
(602) 933-2492
Board Certification:
Pediatric Hematology/Oncology; General Pediatrics


Dr. Boklan has been a faculty member at Phoenix Children's Hospital since 2001. Her clinical focus is on leukemia, with an emphasis on the various types of myeloid leukemias. She is Co-Director of the hospital's Leukemia Program. Dr. Boklan also specializes in care for children with bone marrow failure syndromes including aplastic anemia. In addition to her areas of clinical focus, Dr. Boklan is Director of Clinical Oncology Research where she supervises all oncology clinical trials carried out at PCH. Her specific interest is in early drug development. As Director of the Early Drug Development Program, she concentrates on evaluating new drugs for patients who do not respond to currently available pediatric cancer treatments.

Dr. Boklan grew up in New York. She obtained her BA in Biochemical Sciences with honors from Harvard University. As an undergraduate, she spent two years in a laboratory, studying the molecular underpinnings of cancer development. She was awarded the Eliot House thesis prize for her work. Dr. Boklan received her MD from New York University School of Medicine where she was elected to the Alpha Omega Alpha Honor Society as well as earning numerous other academic achievement awards. Dr. Boklan then completed her residency in pediatrics at Children's Hospital of Philadelphia followed by her pediatric hematology-oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) and New York Hospital. Dr. Boklan's fellowship research involved stem cell gene therapy and looking at new approaches for molecularly-targeted cancer treatment. Following completion of her fellowship, Dr. Boklan spent an additional year continuing her research at MSKCC as the Charles H. Revson Fellow in Biomedical Research and Charles A. Dana Postdoctoral Research Fellow.

Dr. Boklan subsequently moved across the country to Phoenix, where she joined the faculty of Phoenix Children's Hospital. Since her arrival, she has built the oncology clinical research program into one with international recognition and membership in multiple prestigious consortia alongside some of the world's major pediatric cancer centers. She currently serves as the PCH Principal Investigator for the Children's Oncology Group (COG), the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) and Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL). Dr. Boklan works with her clinical partners in other academic centers as well as pharmaceutical companies to develop studies with the most promising agents available and bring them to pediatric patients. She also works closely with her laboratory collaborators to investigate new targeted agents and determine which would be best to move forward into clinical trials.

When Dr. Boklan is not running around caring for patients or supervising trials, she can be found in the hallways playing with her furry associates. Dr. Boklan also serves as the Medical Advisor for the PCH's Animal Assisted Therapy Program.


Education & Training

Back to Top
Board Certification:
Pediatric Hematology/Oncology; General Pediatrics
Medical School / Education:
New York University School of Medicine, New York, NY
Children's Hospital of Philadelphia, Philadelphia, PA
(Pediatric Hematology/Oncology) Memorial Sloan-Kettering Cancer Center, New York, NY


Back to Top
Research / Special Interests:
Leukemia, Bone Marrow Failure, New Cancer Drug Development

Select Publications

Back to Top
Boklan J. Little Patients, Losing Patience: Pediatric Cancer Drug Development. Commentary. Molecular Cancer Therapeutics. August 2006, Vol 5(8); 1905-1908.

Gao S, Mobley A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen speci

Academic Affiliations

Back to Top
Assistant Professor of Clinical Pediatrics, University of Arizona College of Medicine, Tucson, AZ; Associate Member, Arizona Cancer Center

Share this page: